|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | hazomib, an investigational oral proteasome inhibitor ( PI ), in combination with lenalidomide and dexamethasone ( IRd ), significantly extends progression-free survival ( PFS ) for patients ( Pts ) with relapsed and/or refractory multiple myeloma ( RRMM ) : the phase 3 tourmaline-MM1 study ( NCT01564537 ) 显示文摘 | Moreau P Masszi T Grzasko N | 2015 | Blood2015，126，23： | 1 |
| 2 | Early complications afterHSCT 显示文摘 | Appcrley J C E Ciluckman E Masszi T | 2012 | The liBMT Handbook 6th Edition Hcmatopoctic StemCell Transplantation2012，2012，： | 1 |
| 3 | Belinostat,a novel pan-histone deacetylase inhibitor (HDACi),in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL):results from the BELIEF trial显示文摘 | O'Connor OA Masszi T Savage KJ | 2013 | J Clin Oncol2013，，： | 1 |
| 4 | Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma显示文摘 | MOREAU P MASSZI T GRZASKO N et ol | 2016 | N Engl J Med2016，374，17： | 1 |
| 5 | Angiotensin Ⅱ activates the human rennin promoter in an in vitro model: the role of c-Jun-Nterminal kinase 显示文摘 | Terebessy T Masszi A Fintha A | 2004 | Nephrol Dial Transplant2004，19，9： | 1 |
| 6 | Ixazomib, an investigational combination with lenalidomide and dexamethasone (IRd), significantly extents progression free survival (PFS) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 Tourmaline-MM study (NCT 01564537) 显示文摘 | Moreau P Masszi T Grzasko N oral proteasome inhibitor (PI) in | 2015 | Blood (ASH annual meeting Abstracts)2015，126，23： | 1 |
| 7 | Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or - intolerant chronic myeloid leukemia in accelerated phase or blast crisis显示文摘 | NICOLINI FE MASSZI T SHEN Z | 2012 | Leuk Lymphoma2012，53，5： | 1 |
| 8 | Belinostat, a novel panhistone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (RiR PTCL): results from the BELIEF trial显示文摘 | O'Connor OA Masszi T Savage KJ | 2013 | J Clin Oncol2013，31，18： | 1 |
| 9 | An Alu-mediated novel large deletion is the most frequent cause of type 3 von Wille- brand disease in Hungary 显示文摘 | Mohl A Marschalek R Masszi T | 2008 | J Thromb Haemost2008，6，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员